EA033304B1 - Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента - Google Patents

Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента

Info

Publication number
EA033304B1
EA033304B1 EA201691570A EA201691570A EA033304B1 EA 033304 B1 EA033304 B1 EA 033304B1 EA 201691570 A EA201691570 A EA 201691570A EA 201691570 A EA201691570 A EA 201691570A EA 033304 B1 EA033304 B1 EA 033304B1
Authority
EA
Eurasian Patent Office
Prior art keywords
axl
pharmaceutical composition
cancer
another embodiment
active ingredient
Prior art date
Application number
EA201691570A
Other languages
English (en)
Other versions
EA201691570A1 (ru
Inventor
Томохиро Егути
Масамити Мори
Йоко Ямаки
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201691570A1 publication Critical patent/EA201691570A1/ru
Publication of EA033304B1 publication Critical patent/EA033304B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Проблема: обеспечивают фармацевтическую композицию для лечения AXL-связанного рака, в другом аспекте фармацевтическую композицию для лечения рака с высокой экспрессией AXL и в еще одном аспекте фармацевтическую композицию для лечения рака, который приобрел резистентность в отношении терапии противораковыми средствами посредством активации AXL. Средства решения: авторы настоящего изобретения изучали соединения, имеющие AXL-ингибирующее действие, и обнаружили, что специфические диамино-гетероциклические карбоксамидные соединения имеют AXL-ингибирующее действие и что фармацевтические композиции, включающие такие соединения в качестве активного ингредиента, обладают терапевтическим эффектом в отношении AXL-связанного рака, в другом аспекте рака с высокой экспрессией AXL и в еще одном аспекте рака, который приобрел резистентность в отношении терапии противораковыми средствами посредством активации AXL, таким образом, завершив настоящее изобретение.
EA201691570A 2014-02-04 2015-02-03 Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента EA033304B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014019226 2014-02-04
PCT/JP2015/053018 WO2015119122A1 (ja) 2014-02-04 2015-02-03 ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物

Publications (2)

Publication Number Publication Date
EA201691570A1 EA201691570A1 (ru) 2016-11-30
EA033304B1 true EA033304B1 (ru) 2019-09-30

Family

ID=53777926

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691570A EA033304B1 (ru) 2014-02-04 2015-02-03 Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента

Country Status (29)

Country Link
US (2) US11045468B2 (ru)
EP (1) EP3103453B1 (ru)
JP (1) JP6390626B2 (ru)
KR (1) KR102322338B1 (ru)
CN (3) CN113425727A (ru)
AU (1) AU2015215578B2 (ru)
BR (1) BR112016017897A8 (ru)
CA (1) CA2938818C (ru)
CY (1) CY1122968T1 (ru)
DK (1) DK3103453T3 (ru)
EA (1) EA033304B1 (ru)
ES (1) ES2788390T3 (ru)
HR (1) HRP20200662T1 (ru)
HU (1) HUE049437T2 (ru)
IL (1) IL247077B (ru)
LT (1) LT3103453T (ru)
ME (1) ME03775B (ru)
MX (1) MX363543B (ru)
MY (1) MY193536A (ru)
PH (1) PH12016501527B1 (ru)
PL (1) PL3103453T3 (ru)
PT (1) PT3103453T (ru)
RS (1) RS60150B1 (ru)
SG (1) SG11201606413RA (ru)
SI (1) SI3103453T1 (ru)
TW (1) TWI655945B (ru)
UA (1) UA120607C2 (ru)
WO (1) WO2015119122A1 (ru)
ZA (1) ZA201605379B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425727A (zh) * 2014-02-04 2021-09-24 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
SI3318259T1 (sl) 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje
ES2894691T3 (es) * 2015-11-04 2022-02-15 Astellas Pharma Inc Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JPWO2022220227A1 (ru) * 2021-04-14 2022-10-20
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128659A1 (ja) * 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
JP2011515397A (ja) * 2008-03-19 2011-05-19 ケムブリッジ・コーポレーション 新規チロシンキナーゼ阻害剤
WO2013040801A1 (zh) * 2011-09-19 2013-03-28 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102446A2 (en) * 2008-02-12 2009-08-20 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CN104066481A (zh) * 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
UA113204C2 (xx) 2012-04-02 2016-12-26 Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції
CA3182876A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
CN113425727A (zh) * 2014-02-04 2021-09-24 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
SI3318259T1 (sl) * 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515397A (ja) * 2008-03-19 2011-05-19 ケムブリッジ・コーポレーション 新規チロシンキナーゼ阻害剤
WO2010128659A1 (ja) * 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
WO2013040801A1 (zh) * 2011-09-19 2013-03-28 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BYERS L.A. et al., An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin. Cancer Res., 2013, Vol.19, No. l, p.279-290, Table 1 *
MOLLARD A. et al., Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors, ACS Med. Chem. Lett., 2011, Vol.2, No. 12, p.907-912, Figure 5. *
YAKES F.M. et al., Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer. Ther., 2011, Vol.10, No.12, p.2298-2308, Table 1. *

Also Published As

Publication number Publication date
LT3103453T (lt) 2020-05-11
EP3103453A4 (en) 2017-09-06
KR20160110498A (ko) 2016-09-21
IL247077B (en) 2020-08-31
DK3103453T3 (da) 2020-04-20
HUE049437T2 (hu) 2020-09-28
PH12016501527A1 (en) 2017-02-06
US11045468B2 (en) 2021-06-29
BR112016017897A8 (pt) 2020-06-30
HRP20200662T1 (hr) 2020-10-02
PL3103453T3 (pl) 2020-06-29
KR102322338B1 (ko) 2021-11-05
PT3103453T (pt) 2020-05-06
US11925638B2 (en) 2024-03-12
WO2015119122A1 (ja) 2015-08-13
EA201691570A1 (ru) 2016-11-30
JPWO2015119122A1 (ja) 2017-03-23
CN105939714A (zh) 2016-09-14
US20210290618A1 (en) 2021-09-23
EP3103453A1 (en) 2016-12-14
CN116509866A (zh) 2023-08-01
TW201613594A (en) 2016-04-16
ES2788390T3 (es) 2020-10-21
SG11201606413RA (en) 2016-09-29
CA2938818C (en) 2023-03-07
MX2016010134A (es) 2016-10-07
CY1122968T1 (el) 2021-10-29
MX363543B (es) 2019-03-27
CN113425727A (zh) 2021-09-24
AU2015215578A1 (en) 2016-08-18
SI3103453T1 (sl) 2020-10-30
NZ722750A (en) 2020-11-27
PH12016501527B1 (en) 2017-02-06
JP6390626B2 (ja) 2018-09-19
EP3103453B1 (en) 2020-04-01
MY193536A (en) 2022-10-18
US20160339020A1 (en) 2016-11-24
ZA201605379B (en) 2018-05-30
IL247077A0 (en) 2016-09-29
AU2015215578B2 (en) 2019-07-11
TWI655945B (zh) 2019-04-11
UA120607C2 (uk) 2020-01-10
ME03775B (me) 2021-04-20
CA2938818A1 (en) 2015-08-13
AU2015215578A2 (en) 2016-10-20
RS60150B1 (sr) 2020-05-29

Similar Documents

Publication Publication Date Title
EA033304B1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
TW201613901A (en) New compounds
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017009608A (es) Compuestos anticancerigenos.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
IN2013MU03118A (ru)
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
MX2020002812A (es) Abx196 para usarse en el tratamiento del cancer de vejiga.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.
TH169730B (th) องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารประกอบ ไดอะมิโนเฮเทอโรไซคลิกคาร์บอกซาไมด์ดังส่วน ผสมออกฤทธิ์

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): TM